A collaborative effort between Fuzionaire Diagnostics, McGill University and The Neuro (Montreal Neurological Institute-Hospital) will foster the development of a new class of radioactive molecules — called radiochemicals — for the diagnosis and treatment of neurodegenerative diseases, including Parkinson’s disease.
Radiochemicals are compounds prepared with radioactive elements that are used for medical applications, such as tracers in positron emission tomography (PET) scans. PET scan is an imaging technique that uses small amounts of radioactive materials, a special camera and a computer to help detect emitted radiation and image biological function in vivo.
